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Abstract
The expansion of tools against HIV transmission has
brought increased interest in epidemiological models
that can predict the impact of these interventions.
The EMOD-HIV model was recently compared to
eleven other independently developed mathematical
models of HIV transmission to determine the extent
to which they agree about the potential impact of ex-
panded use of antiretroviral therapy in South Africa.
Here we describe in detail the modeling methodology
used to produce the results in this comparison, which
we term EMOD-HIV v0.7. We include a discussion
of the structure and a full list of model parameters.
We also discuss the architecture of the model, and its
potential utility in comparing structural assumptions
within a single modeling framework.
1 Introduction
This document provides a detailed description of the
“EMOD-HIV” population model of HIV that was
compared to several other HIV models in a recent ar-
ticle by Eaton et al. published in PLoS Medicine [1].
The EMOD-HIV model was designed by researchers
in the Epidemiological Modeling group at Intellectual
Ventures Laboratory as part of a larger effort to en-
able broad accessibility of modeling and quantitative
analysis tools for planning and execution of infectious
disease control. The group has thus far developed
mathematical models of malaria [2], polio, and tuber-
culosis in addition to HIV. The models and their ac-
companying software infrastructure are designed pri-
marily for use by disease modelers, researchers, epi-
demiologists, and public health professionals seeking
to simulate infectious disease conditions and evaluate
the effectiveness of different eradication or mitigation
approaches.
This document describes only the HIV transmis-
sion model, and not the other diseases, parallel com-
puting infrastructure, or additional features of the
software not utilized in the Eaton 2012 model com-
parison.
The Eaton 2012 model results from EMOD were
generated from a preliminary version of the model,
which we will denote v0.7. While v0.7 includes all the
basic elements of a HIV simulation, to be discussed
shortly, it lacks some elements that could have added
heterogeneity to behavior and biology of HIV trans-
mission, such as variable viral loads and disease stage
durations. Additionally, the model parameters were
calibrated using a rudimentary search algorithm that
did not allow for parameter uncertainty to be incor-
porated in error bound calculations. More detailed
and systematically calibrated versions of the model
are in progress. Outputs from v0.7 should be consid-
ered preliminary.
2 Overview of the Model
EMOD-HIV v0.7 is an individual-based stochastic
simulation of sexual and vertical HIV transmission
implemented in C++ and parameterized for the set-
ting of South Africa. More specifically, v0.7 targets
South Africa at a national level, with sexual mix-
ing parameters based on data from KwaZulu-Natal
province.
Geographic distribution of the population was not
explicitly modeled in v0.7, but an explicit network of
human relationships was formed based on pair forma-
tion rules, and allowed to evolve over time. Though
capable of modeling homosexual partnerships and
commercial partnerships (in which providers are dis-
tinguished from patrons), v0.7 utilized only het-
erosexual relationships due to their importance in
the modern sub-Saharan Africa transmission setting
[3]. Thus, HIV transmission could only result from
heterosexual intercourse or mother-to-child vertical
transmission in v0.7. Three types of heterosexual re-
lationships were modeled, each characterized by dif-
ferent distributions for ages of entrants, durations,
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Figure 1: The EMOD-HIV model is designed to cleanly separate components related to the contact network
(Network) from within-host biology of HIV infection (Intrahost). Both of these build upon a generic “Per-
son” whose properties are more broadly applicable in epidemiological models (e.g., age, gender, and vital
statistics). This Person object is specialized into “STI Person,” containing attributes related to behavior
within the contact network and potentially applicable to other STIs, and a further specialized “HIV Person”
object containing attributes that are specific to the biology of HIV. Interventions can modify factors in both
modules that influence transmission, such as the rates of condom use or use of antiretroviral therapy. In
v0.7, each HIV-discordant interaction is modeled explicitly, and the transmission probability is calculated
based on behavioral factors (type of sexual contact, condom use, etc.) and biological factors (stage of HIV
disease, co-infections, ART, etc.) after interventions are applied.
and levels of concurrency. The youngest, shortest-
duration relationship type was most likely to permit
the individuals to simultaneously seek additional re-
lationships. Thus, although the propensity to form
multiple simultaneous partnerships was not explicitly
age-dependent, the types of partnerships preferred
by younger individuals implicitly increase their like-
lihood to enter concurrent partnerships.
The remainder of this article describes the EMOD-
HIV v0.7 model in detail, with subsections for demo-
graphics, individual properties, the pair formation al-
gorithm, relationship flow, sexual relationships, sex-
ual acts, HIV transmission, HIV infection (with and
without treatment), and the antiretroviral therapy
(ART) intervention. The article concludes with a
brief discussion of future work.
3 Detailed Model Description
3.1 Model Structure
The EMOD-HIV model propagates forward in time
using a combination of discrete events and time steps.
Discrete events, implemented using C++11 lambda
expressions, allow for one or more function calls to
be scheduled for execution at a future time in the
simulation.
As with all the EMOD disease models, the HIV
model utilizes object-oriented programming design
principles such as interfaces, factories, and observers
to achieve a highly modular architecture, thus en-
abling comparisons of structural assumptions and dif-
ferent levels of model detail. For example, parameters
specific to the within-host biology of disease progres-
sion and to behavioral propensities that drive pair
formation have been separated into different inher-
itance classes. Thus, modules or sub-modules can
be interchanged while leaving other portions of the
model intact. Figure 1 provides diagram of the archi-
tecture, the components of which will be discussed in
detail in the sections that follow.
3.2 Demographics
Vital dynamics within the EMOD-HIV model are
derived from fertility and mortality tables that are
passed to the model as input. In v0.7, these val-
ues came from the Actuarial Society of South Africa
(ASSA) AIDS and Demographic Model [4], using
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linear interpolation between age-specific data points
from ASSA to construct a cumulative probability dis-
tribution function (CDF) of death date from a per-
son’s date of birth. Upon instantiation, individual
agents in the model sample stochastically from this
CDF using an inverse transform of this distribution.
Female agents similarly sample the age at next child-
birth, if any, upon instantiation and birth of a pre-
vious child. Pregnancy is not linked to relationship
status in v0.7, although newly born individuals are
linked to a mother. The fertility rate changes by
simulation year and female age, and the available es-
timates range from 1980 to 2020. Values outside of
this range were chosen by “clamping” - i.e., choosing
the nearest value within the range. Clamping was
also used when necessary to determine the non-AIDS
mortality rate, which varies by gender, age, and sim-
ulation year.
Mother-to-child transmission (MTCT) is enabled
in v0.7 using the linkage between the mother and off-
spring created by the demographics module. The
baseline rate of MTCT is 1 in 3 births [5, 6, 7].
Antiretroviral therapy (ART) reduces the transmis-
sion rate to 1 in 100 births [8], except in the final
9 months prior to death due to ART failure, when
it is assumed to have no effect on MTCT because
HIV-related death after ART initiation is assumed to
occur due to virological failure. (As we will show,
many individuals do not reach the time of virological
failure and death on ART because non-HIV mortal-
ity occurs at an earlier time - i.e., they achieve a
normal lifespan while on ART.) Additionally, 45% of
mothers not on ART receive single-dose Nevirapine
prophylaxis (sdNVP), which reduces the MTCT rate
to 1 in 10 births [9, 10, 11].
3.3 Individual properties
Individuals within the simulation have a variety of
properties, represented by continuous or discrete
state variables. Some properties are static through-
out life, and others dynamically change through the
course of the simulation either in response to ag-
ing or simulation events such as infection. Included
in these properties are complex dynamic objects
for HIV infection and relationships, to be described
shortly. Static properties are assigned upon instanti-
ation (simulation initialization or birth after the be-
ginning of the simulation) and include gender, time of
birth, time of non-HIV death, STI co-infection, and
male circumcision. In v0.7, the latter two are sampled
randomly at birth with respective probabilities of 7%
and 42% [3]. Dynamic properties include HIV status,
history of ART program participation and drop-out
if applicable, and relationship participation.
3.4 The Pair Forming Algorithm
Individuals enter a sexually active state at an age
randomly sampled from a Weibull distribution with
a shape parameter of 20 and a mean age of 16.5 years
and 15.5 years for males and females, respectively,
and never permitting sexual activity earlier than 13
years of age [3, 12, 13, 14]. These values were deter-
mined by calibration, using national survey results as
a prior [3, 12, 14, 15, 16]. Individuals that have ex-
ceeded their stochastic sexual debut age are able to
enter into three types of sexual relationships: tran-
sitory, informal, and marital. Three Boolean static
properties of individuals, termed “extra-relational
flags,” determine whether an individual can enter ad-
ditional concurrent relationships while participating
in a relationship of each of the three types. In v0.7,
these flags are stochastically assigned at instantiation
with probabilities of 80%, 30%, and 10% for transi-
tory, informal, and marital relationships, respectively.
Note that these flags indicate the ability of an in-
dividual to participate in concurrent relationships,
and were determined by calibration, but the resulting
point prevalence of concurrency ends up close to val-
ues found in [12]. These extra-relational flags create
heterogeneities in HIV risk: an individual who re-
ceives all three flags, for example, would be likely to
participate in many more lifetime partnerships than
one who receives no flags.
The algorithm used to take individuals seeking re-
lationships and form pairs is called the pair forma-
tion algorithm (PFA). Each of the three relationship
types uses the same PFA algorithm, but operates on
different data about the age distribution and age gaps
within partnerships.
PFA takes as input a matrix, called the matrix of
partnership age distributions (MOPAD), in which the
entry at position (i, j) is the probability of a male of
age bin i pairing with a female of age bin j. The three
MOPADs used in the can be seen in Figure 2(a-c) and
are based on published data by Ott et al. from the
Africa Centre for Health and Population Studies [17].
Ott et al. report their data in 5-year age bins; these
were sub-divided to 2.5-year age bins, shifted to rep-
resent incident rather than prevalent relationships,
and smoothed using a Gaussian kernel. Membership
in an age bin was determined based on each individ-
ual’s time of birth.
Individuals enter the PFA seeking a relationship,
and are immediately placed into a gender-specific
queue, see Figure 3. There is a single queue for
all males, and for females, there are separate queues
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Figure 2: Transitory (left column), informal (middle column), and marital (right column) relationships are
characterized by their matrix of partnership age distributions (MOPAD, top row) and by their Weibull-
distributed duration (bottom row; note the difference in scale on the time axis). On average, transitory
relationships recruit the youngest individuals, create the smallest age gap between partners, and have the
shortest durations, while marital partnerships recruit the oldest individuals, create the largest age gap
between partners (approximately 5 years), and have the longest durations.
for each 2.5-year age bin. The queues fill over a pe-
riod of time (fourteen days for marriage and one day
for transitory and informal), after which relationships
are formed by a processing step. The processing step
works linearly through the male queue, starting from
individual at the head of the queue. A female part-
ner for the head male is determined based on age
and availability. More specifically, a male of age bin
m samples a partner age bin, f , from
p(F = f) ∝
{
p(F = f |M = m) if Nf > 0
0 otherwise.
(1)
Here, Nf is the number of females queued in age bin f
and p(F = f |M = m) is the conditional distribution
derived from the MOPAD. If p(F = f) is identically
zero, the male remains in the queue for the next pro-
cessing round. Otherwise, the female of the sampled
age bin who has been waiting the longest is selected
as the partner. The paired individuals are removed
from their respective queues, and the process is re-
peated.
3.5 Relationship Flow
The pair formation algorithm can produce relation-
ships distributed according to the MOPAD matrix
only if the males and females entering the algo-
rithm have age distributions that match the respec-
tive marginals of the MOPAD, and the total num-
ber of females matches the total number of males.
The (exponential) rates at which individuals in each
age bin and gender enter for each relationship type
are adjusted daily to form the relationships dictated
by the MOPAD. The MOPAD dictates only the rel-
ative number of relationships formed between pairs
of different ages, but not the absolute number of re-
lationships formed by the PFA. This total through-
put of relationships formed is set such that the ex-
pected number of individuals seeking a relationship
of a particular type, after rate adjustment to meet
the MOPAD, matches the number of males and fe-
males that would have sought that relationship had
the rates not been adjusted for the MOPAD. These
unadjusted rates are listed in Table 1. Thus, the
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Figure 3: A diagram of the Pair Formation Algorithm
(PFA). Males and females enter from the left. Males
form a single queue, while females are sorted into
queues according to their age, represented above as
labeled arrows. Males and females accumulate in the
order they entered and remain in their queues until
the PFA is processed. Processing takes place once per
day in the transitory and informal PFAs, and once
every 14 days in the marital PFA. During processing,
the individual at the head of the male queue selects
a partner based on his MOPAD-derived conditional
probability weighting (represented by dashed green
lines). The paired individuals exit the algorithm to
the right. Only individuals with no available partners
of their chosen type are left in queues after processing
is complete.
MOPAD adjustment changes the age distributions of
the individuals seeking relationships, but not the to-
tal number of each type of relationship formed.
This adaptive daily rate control allows the model
to automatically discover the rates of relationship en-
try that are consistent with the MOPAD. It is con-
ceivable, however, that events causing large demo-
graphic shifts might change the MOPAD. For exam-
ple, when comparing simulations with universal HIV
treatment versus no treatment, it is conceivable that
demographic influence of the disparate AIDS death
tolls should cause the MOPADs to diverge. There-
fore, adaptive rate control is disabled after an initial
burn-in period of 15 years, after which the entrance
rates remain fixed at their final controlled values and
the MOPAD is permitted to change as the simulation
progresses.
The calculation of the total relationship formation
rate (Table 1) and adjustment of individual relation-
ship entry rates are based only on individuals eligible
to form a new relationship. Eligibility to form a new
relationship depends on several factors. Individuals
that have not surpassed their debut age are not eligi-
Table 1: Base exponential relationship formation
rates and Weibull dissolution distribution parame-
ters.
Duration
Rate Mean Shape
(per year) (per year)
Transitory 1/2 1/0.9 1.2
Informal 1/1.9 1/1.8 2.0
Marital 1/30 1/20 1.5
ble for any relationships, and all individuals must be
at least 15 years old to marry. Post-debut individuals
who are not already in a relationship are eligible to
add any of the three relationships. Young individuals
(e.g. < 20) will tend to enter a transitory relationship
and older individuals (e.g. > 40) will tend to enter a
marital relationship due to their different age distri-
butions shown in Figure 1.
Once in a relationship, the previously described
Boolean concurrency flags determine if the individu-
als is allowed to add additional (concurrent) relation-
ships, after a waiting period of 60 days. For example,
if the transitory concurrency flag is true, the individ-
ual is allowed to add additional relationships of any
type as long as their only ongoing relationships are
of transitory type. Coital dilution, discussed later, is
applied to any concurrent partnerships, and the max-
imum number of simultaneous relationships restricted
to three transitory, two informal, and one marital re-
lationship(s). Note that, under these assumptions, a
small subset of the population will have all three flags
true, and comprises an especially high-risk subgroup.
Note also that in this model, the formation of a mar-
ital partnership, which has the lowest probability of
permitting concurrency and the longest duration, will
often “protect” individuals from taking on additional
partnerships later in life.
3.6 Sexual Relationships
Sexual relationships are instantiated by the three
PFAs and have characteristics including the partic-
ipating individuals, condom usage rate, formation
time, and scheduled breakup time. When the re-
lationship forms, its breakup time is sampled from
a PFA-type-dependent Weibull distribution, see Fig-
ure 2(d-f). The mean and shape parameters of these
distributions are listed in Table 1. Note that relation-
ships can terminate early if either partner dies, and
the surviving partner is treated as eligible, equiva-
lently to a someone who has become eligible through
a relationship breakup.
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Table 2: Sigmoidal condom ramp parameters.
Low (l) High (h) Middle Year (t0) Rate (r)
Transitory 0.0125 0.6375 1999 0.3
Informal 0.0125 0.5125 1999 0.25
Marital 0.000625 0.200625 2002 0.225
Each sexual relationship has a fixed condom usage
probability, called the base rate, which is determined
at the time the relationship is created. The func-
tional form of the base condom usage probability is
an increasing sigmoid,
P (t) =
h
1 + e−R(t−t0)
+ l, (2)
the parameters of which depend on the type of re-
lationship (see Table 2). The relationship type-
dependence of these parameters is to account for the
fact that condom usage is lower in longer-term re-
lationships, while the time-dependence accounts for
reported increases in condom usage over time. Self-
reported condom usage probabilities vary greatly.
The values in Table 2 come from calibrating param-
eters that were initially determined from data given
in the 2002, 2005, and 2008 HSRC national surveys
[3, 14, 15].
For half of the relationships with a base rate above
10% and below 90%, a modified rate of either 10%
or 90% was used to add additional heterogeneity by
increasing the variance. This was implemented in a
way that ensured that the expected condom usage
probability remained equal to the base rate.
3.7 Coital Acts
Individual coital acts are simulated for HIV-
discordant relationships only. When an individual be-
comes infected, the discordancy states of all relation-
ships involving the individual are updated. Within
HIV-discordant relationships, the base time between
coital acts is exponentially distributed with a mean
of three days [18]. For individuals in two, three, or
four-plus concurrent partnerships, our model addi-
tionally accounts for coital dilution, i.e., a negative
correlation between the number of simultaneous part-
nerships and the frequency of coital acts within these
partnerships [19, 20]. While some studies suggest a
very strong effect of coital dilution [21, 22], others
find little evidence for this phenomenon [23, 24]. We
therefore chose a relatively modest parameterization
of coital dilution, in which the act frequency per rela-
tionship for an individual belonging to two, three, or
four (or more) concurrent relationships is multiplied
by 0.75, 0.60, and 0.45, respectively. Condom usage is
assigned to each coital act based on the relationship’s
usage probability, and higher-risk anal intercourse is
selected 2% of the time.
3.8 Stages of HIV Infection
We assume three stages of untreated HIV infection:
acute, latent, and AIDS. In v0.7, the durations of the
acute and AIDS stages are 2.9 months and 9 months,
respectively, for all individuals [25]. The total sur-
vival time with HIV is sampled stochastically based
on the individual’s age at the time of infection (dis-
cussed below), and the duration of the latent phase
is the total survival time minus the duration of the
acute and AIDS stages. If the total survival time is
shorter than 11.9 months, then the AIDS phase is
shortened, and in rare cases when survival is shorter
than 2.9 months, the remaining acute phase is short-
ened to fit within the survival duration.
3.9 HIV Transmission
The probability of HIV transmission within a dis-
cordant relationship is calculated on a per-act basis
and varies by disease stage. The per-act transmission
probabilities for the acute, latent, and AIDS stage are
3.4E − 2, 1.3E − 3, and 9.4E − 3, respectively. The
relative magnitude of these values in each stage of
disease comes from the per-time transmission rates
measured in HIV-discordant couples in Uganda [25].
These probabilities have been multiplied by the in-
verse act frequency and increased by 50% as a result
of the model calibration process. Note that these
transmission probabilities apply in the absence of any
interventions or other cofactors. The per-act trans-
mission probability is multiplied by applicable act-
dependent factors, which are described in Table 3.
There is no gender bias in transmission other than
the male circumcision cofactor, which reduces the cir-
cumcised male’s HIV acquisition probability by 60%
[26, 27, 28].
If the HIV positive individual is on ART and not
experiencing treatment failure, then the transmission
probability per act is set to 4% of the latent-stage
transmission probability [29]. When failing ART, the
6
Table 3: Cofactors used in determining the HIV transmission probability.
Cofactor Transmission Probability Multiplier
Male circumcised (F→M transmission only) 0.4
STI present 4.0
Condom used 0.1
Anal intercourse (infected receptive female partner) 4.0
Anal intercourse (infected insertive male partner) 10
0
20
40
60
80
0
5
10
15
20
0
0.1
0.2
0.3
0.4
0.5
Age at time of
seroconversion
Years since
seroconversion
Probability of death
due to HIV
Figure 4: The untreated HIV prognosis of an individual is determined at the time of infection using this
age-dependent distribution. Before age 15, a sum of two weighted Weibull distributions is used to represent
the typically bimodal survival time of children. Beyond age 15, survival time is Weibull-distributed, with
older individuals having a shorter average survival time. Note that untreated HIV-infected individuals die at
the end of their HIV prognosis or their normal lifespan (determined by the demographics module), whichever
occurs earlier.
transmission probability is set to the AIDS transmis-
sion probability.
3.10 Survival with Untreated HIV In-
fection
HIV prognosis is both heterogeneous and highly age-
dependent [30, 31, 32], and is therefore sampled from
an age-dependent distribution, shown in Figure 4.
For individuals over the age of 15, the distribution
is Weibull-distributed with shape parameter κ set to
2 and an age-variable scale parameter λ varying with
age a (in years) as follows [30]:
λ = 21.182− 0.2717a (3)
For those under 15, the distribution is a convex
combination of two Weibull distributions,
λ1 = 1.515 + 1.039a (4)
κ1 = 0.97 + 0.0687a (5)
λ2 = 10.0 + 0.474a (6)
κ2 = 5.39− 0.226a, (7)
distinguishing infant mortality and later child mor-
tality [33]. The first distribution is used 65% of the
time.
CD4+ T-cell count is time-dependent based on the
fraction remaining of the individual’s prognosis f ,
calculated by dividing the time since infection by the
total HIV prognosis. It drops to 594 cells/µL imme-
diately upon infection to represent very rapid CD4 T-
cell depletion (and partial rebound) during the acute
phase (the detailed timecourse of which is not mod-
eled here), and decreases down to 59 cells/µL at death
as follows:
CD4(cells/µL) = (24.363− 16.672f)2. (8)
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3.11 HIV Infection (with ART)
Mortality for individuals receiving ART is determined
using a multivariate Cox proportional hazards model
from the International Databases to Evaluate AIDS
- South Africa [34, 35], which takes as input the in-
dividual’s age, gender CD4 count, and body weight
to estimate the prognosis. Note that this database
utilizes ecological studies of ART efficacy, and thus
includes “real-world” factors such as poor adherence,
co-morbidities, misuse of ART, undetected drug re-
sistance, etc., which may contribute to mortality on
ART and not be captured in randomized controlled
trials.
In addition to the individual’s age and gender, the
WHO stage and body weight are estimated by as-
suming individuals progress from the pre-infection
state through WHO stages from one to four stochas-
tically, with the interval from WHO stage 1 to 2,
2 to 3, and 3 to 4 samples from a Weibull distri-
bution with shape parameters 0.26596, 0.19729, and
0.34721, respectively, and scale parameters 0.96604,
0.99160, 0.93560, respectively [36]. Any remaining
pre-treatment survival time is spent in WHO stage 4.
Body weight is assumed to decline according to the
midrange values of the WHO AIDS staging guide-
lines: from a pre-infection weight of 65 kg to 62.1 kg
in Stage 1, 57 kg in Stage 2, 50 kg in Stage 3, and
40.1 kg in Stage 4. Calculation of CD4 decline was
described earlier (see Section 3.10).
The survival time, s, for an individual on ART was
calculated as [35]:
s(years) =
(
123.83
m2.9
)
log
(
1
r
)2.9
, (9)
in which r is a uniformly distributed random number
between 0 and 1, and m is the appropriate multi-
plier applied for the individual based on the condi-
tions listed in Table 4. Mortality while on ART is
assumed to be associated with a period of virologi-
cal failure with the same duration and infectivity as
the late-stage AIDS phase of untreated disease. For
a majority of individuals, this period is longer than
their HIV-independent survival, such that they never
survive to realize the higher-infectivity phase at the
end of successful viremic suppression by ART.
In the event of dropout from the ART program, an
individual’s recovery while on ART is represented by
an increase in their CD4 count, which occurs inde-
pendently of their starting CD4 count and saturates
after three years on ART [37, 38, 39, 40, 41]. The
increase is calculated as [37]:
CD4 increase(cells/µL) = 15.584t− 0.2113t2, (10)
Condition Multiplier
WHO Stage 3 or 4 2.7142
Age > 40 years 1.4309
Female gender 0.6775
CD4 at enrollment
25-49 0.7497
50-99 0.4258
100-199 0.3068
200+ 0.2563
Table 4: Multipliers used in survival time calculation.
in which t represents the time, in months, that the
individual has received ART. The increase saturates
after 36 months and does not allow the individual
to exceed their pre-infection CD4 count. CD4 recon-
stitution is used to compute the untreated prognosis
following dropout from the ART program, essentially
turning back the clock on the infection to the fraction
of remaining prognosis that corresponds to this CD4
count.
When an individual is re-enrolls in an ART pro-
gram after a prior dropout, the process to re-compute
the ART prognosis is identical to the initial enroll-
ment; however, the individual’s prognosis parameters
may change as the individual will have aged in the in-
tervening time.
3.12 ART Intervention
The ART intervention was prescribed by the Mod-
elling Consortium organizers [1]. CD4 thresholds for
treatment eligibility are 200 cells/µL, 350 cells/µL,
and immediate. Once eligible, an individual samples
an enrollment date from an exponential distribution
with one-year mean. A fraction of the population is
not allowed to enroll, as prescribed in the guidelines.
ART is not distributed preferentially by age, gender,
or any other criteria than CD4 threshold. Of indi-
viduals dropping out of the ART program, 50% are
eligible to re-enroll. See Eaton et al. 2012 for a de-
tailed discussion of the interventions modeled in the
study [1].
3.13 Timecourse of a Simulation
The timecourse of each simulation run is depicted
graphically in Figure 5. Simulation begins in year
1960 to allow ample time for relationships to “burn-
in.” During the period between 1960 and 1975, the
relationship formation rates for each gender and rela-
tionship type are updated daily using the relationship
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Figure 5: The process of an EMOD-HIV simulation is depicted graphically. After initialization steps such as
memory allocation and parsing of input files, the simulation begins in 1960. Newly instantiated individuals
with demographic properties dictated by the demographics module begin forming relationships at rates that
are adjusted daily based on the MOPAD. After a burn-in period of 15 years, the entrance rate adjustment
is stopped, and the age-dependent entry rates into each PFA are fixed at their 1975 rates for the rest of
the simulation. In 1980, HIV infection appears in 5% of the population at random, with their time since
infection sampled uniformly from their total untreated HIV prognosis. This high initial seeding of infection
was used to offset the disproportionate number of low-risk infections created by this method of seeding the
early epidemic. The intervention (ART distribution according to a variety of criteria and coverage levels)
is applied instantaneously in 2012, and the simulation continues until 2050. Output files from numerous
simulations are combined for statistical analysis in Matlab.
flow algorithm. Adjustment of PFA entry rates is ter-
minated in 1975, and the rates are fixed at their 1975
values for the remainder of the simulation.
Infections are seeded in year 1980. The seeding
process infects 5% of the population according to
the age and gender distribution reported in the 2008
HSRC survey [15]. This prevalence is higher than val-
ues generally accepted for 1980 in South Africa; how-
ever, reproducing the historical trend of HIV preva-
lence would require a model that acknowledges the
behavior change that has occurred from the 1980’s
until the present day as a result of increasing HIV
awareness. These include reductions in commercial
sex work and other high-risk activities, as well as
increases in protective behavior such as condom us-
age, male circumcision, and serosorting-like partner
choice. Since little data is available about behavior
during the early HIV epidemic, we chose not to model
these early-epidemic conditions, and therefore initial-
ized our simulation at artificially high prevalence to
account for the relatively lower-risk individuals who
are initially infected in our model.
The ART intervention is enabled in year 2012. Eli-
gible individuals enroll in ART according to an expo-
nential distribution having a mean of one year. The
ART intervention continues through the conclusion
of the simulation in year 2050.
3.14 Model Calibration
The EMOD-HIV v0.7 calibration process used data
from the 2002, 2005, and 2008 HSRC surveys [3, 14,
15] in addition to antenatal prevalence data from 1990
to 2009 [42]. The parameters that were subject to the
most careful calibration were those to which the epi-
demic trajectory was highly sensitive, but for which
available data is insufficient to know their value with
reasonable certainty. These include the absolute per-
contact transmission rate, the rates of condom use by
year in each relationship type, and the probability of
concurrency in each relationship type.
As previously mentioned, the calibration process
used to generate the results presented in Eaton et
al. 2012 was rudimentary. Parameter values were ini-
tialized to values reported in field studies, even when
these values have high uncertainty and likelihood of
survey bias. Then, a coordinate descent with golden
section search was used to incrementally adjust pa-
rameter values, one at a time, so as to minimize a
squared error loss function. This function penalized
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differences between the simulation output and HSRC
prevalence data by age and gender, and ANC preva-
lence as compared to simulated females aged 25 to 30.
Parameters that are known with the lowest certainty
were prioritized for adjustment.
This approach to calibration worked to a limited
extent, but was unable to resolve co-varying param-
eters. These parameters were adjusted by hand in
order to minimize the same loss function. Subse-
quent versions of the EMOD-HIV model will employ
a sophisticated calibration process that uses Bayesian
methods.
4 Conclusions and future work
The EMOD-HIV model is a work in progress. As-
sumptions have been improved and numerous fea-
tures have been added since the initial Stellenbosch
Modelling Consortium meeting. One area of improve-
ment is model calibration. As previously mentioned,
the model was initially calibrated using a rudimen-
tary algorithm that required much adjustment by
hand. We have since developed a Bayesian calibra-
tion tool based on Incremental Mixture Importance
Sampling [43]. Improved calibration will allow pa-
rameter uncertainty to be included in estimates in ad-
dition to finding appropriate values for key parame-
ters. Future work will build upon the model described
here. Features such as increased detail in our repre-
sentation of STIs and viral-load driven transmission
are planned for the immediate future. Additionally,
the model will soon gain the ability to perform spa-
tial simulation by using the spatial support features
of the EMOD software implemented for all diseases.
Migration between geographic locations, represent-
ing communities, will be built using realistic migra-
tion patterns. Finally, we plan to analyze a variety
of interventions such as circumcision, ART treatment
options, and vaccine candidates.
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A Parameter Table
Parameter Table
Parameter Value Units Comments
General
Initial population 75000 people Individuals uniformly weighted to
represent full S.A. population.
Number of burn-in days 7300 days Days from 1960 to infection seeding
in 1980.
Duration of simulation 32850 days Days from 1960 to end in 2050.
Initial prevalence fraction 5 percent Seeding prevalence, high for 1980 but
gives good 2010 results.
Circumcision probability 42 percent Nationally, 42% of men aged 16-55
years report being circumcised.
STI probability 7 percent Approximates fraction of STI (HSV-
2) infected individuals that would be
shedding.
Minimum age for sexual in-
teraction
13 years Less than 10% have sex before 15
[15]. Sex before 13 is excluded.
Coital frequency 0.33 acts/day Self-reported coital frequency among
discordant couples in Rakai, Uganda
[18].
Network
Male mean debut age 16.5 years Mean debut age for males reported
as 16.3 [16].
Female mean debut age 15.5 years Calibrated from mean debut of 17.2
reported [16].
Days between adding rela-
tionships
60 days Avoids excessive concurrent relation-
ships, calibrated.
Coital dilution with 2 part-
ners
75 percent
Relatively modest parameterization
based on conflicting data
[19, 20, 21, 22, 23, 24].
Coital dilution with 3 part-
ners
60 percent
Coital dilution with 4+
partners
45 percent
Disable entrance rate ad-
justment on sim day
5475 days Rate adjustment ends five years be-
fore seeding.
Transitory relationship for-
mation rate
0.00137 formations/day
Exponentially distributed formation
and Weibull distributed breakups
result in reasonable durations,
relationship prevalence, and
cumulative lifetime number of
relationships. Adjusted during
calibration.
Transitory relationship du-
ration (mean)
0.003044 breakups/day
Transitory relationship du-
ration (shape)
1.2 dimensionless
Informal relationship for-
mation rate
0.001442 formations/day
Informal relationship dura-
tion (mean)
0.001522 breakups/day
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Parameter Table Continued
Informal relationship dura-
tion (shape)
2.0 dimensionless
Marital relationship forma-
tion rate
9.13E-5 formations/day
Marital relationship dura-
tion (mean)
1.37E-4 breakups/day
Marital relationship dura-
tion (shape)
1.5 dimensionless
Transitory PFA processing
interval
1 day
Processing intervals ensure sufficient
partner diversity while avoiding
excessive delays.
Informal PFA processing
interval
1 day
Marital PFA processing in-
terval
14 days
Maximum simultaneous
transitories
3 relationships
Selected during calibration to arrive
at a 50 lifetime partners max while
enabling concurrency. Polygamy is
not enabled.
Maximum simultaneous in-
formals
2 relationships
Maximum simultaneous
marriages
1 relationships
Minimum age for marriage 15 years Marriage before 15 is unusual in
South Africa [16], as reflected in the
marital MOPAD matrix.
Extrarelational probability
transitory
80 percent
Calibrated to get HSRC and ANC
prevalence to align while avoiding
too many lifetime partners.
Extrarelational probability
informal
30 percent
Extrarelational probability
marriage
10 percent
Sexual Transmission
Acute prob transmission
per act
0.034027 prob/act Relative values adapted from analy-
sis of transmission among discordant
couples in Rakai, Uganda [25]; abso-
lute rates adjusted by 1.5 factor dur-
ing calibration, and account for act
frequency of 0.33 acts/day. Values
consistent with meta-analysis [44].
Latent prob transmission
per act
0.001307 prob/act
AIDS prob transmission per
act
0.00937 prob/act
ART viral suppression risk
multiplier
0.04 dimensionless Based on HPTN052 trial [29]
Circumcision risk multiplier 0.4 dimensionless Trials in South Africa, Kenya, and
Uganda [26, 27, 28]
Anal sex probability 2.0 percent 2.3% in men and 1.2% in women re-
ported in US [45].
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Parameter Table Continued
Anal risk multiplier 10 dimensionless 1.4% per unprotected receptive act
from a meta-analysis [46, 47, 44]
STI risk multiplier 4.0 dimensionless 2.58 for those with GUD in Rakai
analysis [48]; 2-5 fold multiplier for
HSV infection [49].
Condom risk multiplier 0.1 dimensionless 80% reduction in incidence [50] and
78% reduction found per act [51]
Vertical Transmission
Usage of sdNVP 45 percent/birth Adherence of 57.1% in Zimbabwe
[52]; 75% adherence in S Africa [53]
Mother to child transmis-
sion on sdNVP
10 percent/birth SWEN trial risk in single dose group
8.98% at 6 months with single dose
NVP; HIVNET 012 11.8% and 15.7%
at 6 week and 18 mo [9, 10, 11].
Mother to child transmis-
sion no intervention
30 percent/birth 30% (range 14-48%) listed in [5, 6, 7,
54].
Mother to child transmis-
sion on ART
3 percent/birth 2.9% at 203 days (excludes infants
born HIV+) [55]; 2.5% at birth and
7.0% at 24 mo in Kisumu breastfeed-
ing study [56]. See also [8].
ART Intervention
Enable ART T or F Varies across intervention scenarios,
false (F) for counterfactual.
Year of ART initiation 2012 Given by intervention scenario.
Exponential ART dropout
rate
0.000263 Varies across intervention scenarios.
Allow ART re-enrollment T Re-enrollment is enabled.
Probability of ART re-
enrollment
50 percent Independent probabilities for each re-
enrollment event.
Condom Sigmoid
Condom low transitory 1.3 percent/act
Values calibrated based loosely on
condom usage data reported in
national surveys.
Condom high transitory 64 percent/act
Condom mid year transi-
tory
1999 year
Condom rate transitory 0.3 1/year
Condom low informal 1.3 percent/act
Condom high informal 51 percent/act
Condom mid year informal 1999 year
Condom rate informal 0.25 1/year
Condom low marriage 6.25E-2 percent/act
Condom high marriage 20 percent/act
Condom mid year marriage 2002 year
Condom rate marriage 0.225 1/year
16
